This is the end of this blog, my man......

but I've created a new one at http://stocksmyman.blogspot.com

Thank you all for taking to to visit this blog but I just felt it was time for some changes, my man.

Still bullish and long on Hard To Treat Diseases (HTDS), my man

I admit that I predicated a few months ago that HTDS would be 0.05 to 0.10 by October, my man. But I still believe HTDS is a worthy investment and I plan to stay with this stock and buy more shares of HTDS.

I hope everyone had a great Thanksgiving, my man

Been out of the loop for two weeks and hope to start posting here again soon. For some reason, Google deactivated my blogger and email account and I had confirm who I was.....bad news for HEB- owners, as the FDA has denied its Ampligen treatment but we can't be too shocked by that.

Sorry I haven't been around, my man

I've been away on family business for the past week and I won't be done until after December 1st. Please don't ask me about any stocks, my man because I probably won't have anything useful to say about it. I really haven't been followin'.

Serve me baby

Vaccines on horizon for AIDS, Alzheimer's, herpes

MARIETTA, Pa. (AP) - Malaria. Tuberculosis. Alzheimer's disease. AIDS. Pandemic flu. Genital herpes. Urinary tract infections. Grass allergies. Traveler's diarrhea. You name it, the pharmaceutical industry is working on a vaccine to prevent it. Many could be on the market in five years or less. Contrast that with five years ago, when so many companies had abandoned the vaccine business that half the U.S. supply of flu shots was lost because of contamination at one of the two manufacturers left. Vaccines are no longer a sleepy, low-profit niche in a booming drug industry. Today, they're starting to give ailing pharmaceutical makers a shot in the arm.......Link to article

No Q3 yet from HTDS....

Been away all day on family business and just got home a short while ago. Didn't see what I had hoped to see. Where's the Q3??? But I'm sticking with HTDS. Today's news about the SFDA is nice but it will be better once we see it on the SFDA site. Stay tuned, my man.

I probably won't be posting much here for the next week or two. GLTA.

Let's hope that HTDS gives us the special treatment by Sunday night, my man

Some random stocks to look at, my man

This morning I was at the computer by 6 AM checking to see if the Q3 was out for HTDS and I was so focused on HTDS that I ignored CARDIO INFRARED TECH (PINK:CDOI) a stock that a spammer was posting about on some of the Google Finance boards. I took a brief look at it and I decided to look into it next week after HTDS was .25 cents a share (OK, if we're lucky it will be 0.05). I never heard of CDOI before but the damn thing did shot up 436.59% today and finished at 0.0220. The dumb thing is, I had plenty of money in my Zecco account to buy CDOI but I was keeping money in reserve for BIEL and HTDS.

Now the same spammer is saying CRITICAL SOLUTIONS (PINK:CSLI) is the "next CDOI" and is going up "500%" on Monday. Never heard of this company either and I'll check them out over the weekend.

I also came across a company called Vyteris Inc. that might be worth a look. Trading at 0.80

Class Action Lawsuit Against Hemispherx Biopharma, Inc.

Sad, my man:

The Complaint charges that defendants violated the federal securities laws. It is alleged in the Complaint that defendants misled investors regarding the status of Hemispherx's New Drug Application ("NDA") for its drug Ampligen with the U.S. Food and Drug Administration ("FDA"). Specifically, defendants failed to disclose that the FDA had requested several reports from the Company before the NDA could even be considered, thus delaying the possible approval of Ampligen by several months at a minimum. Then, on November 2, 2009, when Hemispherx belatedly disclosed this information, the price of the Company's securities fell 20% to close at $1.13 on the next trading day, November 3, 2009. LINK

Monday...November 16, 2009 could be a very big money day, my man

BioElectronics Corp. announced that results from the recently completed acetaminophen comparison study will be released on Monday, November 16th after the close of the market. The study compares the effects of ActiPatch Therapy to acetaminophen in the form of Extra Strength Tylenol for the treatment of Delayed Onset Muscle Soreness (DOMS).

HTDS will file the Q3 financials on Pink Sheets by the due date of November 15, 2009 (which is a Sunday).

We won't know what happens with the BIEL study until after the market and if it's positive we'll have reason to be happy on Monday night. Going into Monday, we'll have some cold, hard facts about HTDS. If they are making money, we are making money, my man. (Though technically speaking HTDS could release the info any time now before Sunday).

Investing in the Biotech Sector: Here’s An Easy Way to Profit from Biotech Stocks

Link to article

Hansen Medical: A Stock to Make Any Investor's Heart Happy

From Seeking Alpha:

"Hansen Medical (HNSN) is not for the fainthearted, but it can work in the speculative part of your portfolio. From $30 two years ago to less than $3 now, it qualifies as one of the recession's bargain-bin candidates. So far this year, it's down from $8. As far as the price goes, it's cheap among the cheap"....LINK

Hansen Medical currently trades at $3.24

Veteran's Day

Stocks To Buy blog, my man

Stocks to Buy A good site to check out, my man

FYI: Financial markets are open on Veterans Day, November 11

LINK

Another ECOtality (ETLY) update, my man

I've posted here before about ECOtality, Inc. (OTCBB: ETLY). The company develops electric vehicle charging infrastructure and unless you've been living in a cave, you know that we'll be seeing more electric vehicles in the coming years. There are only a few companies that do this and ETLY is a steal at 14 cents a share.

Related news:

11/04/09: ECOtality Signs Definitive Agreements for $15.5 Million Capital Raise...Transaction eliminates all $9.1 million of existing debt and provides capital to support ECOtality`s anticipated growth

11/03/09, USA Today: Energy Dept. awards money for electric cars

10/30/09: Nissan is a partner with Scottsdale-based Ecotality

10/26/09: Sufiy.: Mass market for EVs: Nissan races to inaugurate electric-car

HTDS, my man

Obviously some interesting news today. Keep an eye on HTDS tomorrow morning. It would be great to see it go above 0.02 and beyond tomorrow. Though I expect a lot of people will be selling off in the morning. But long-term, HTDS is a keeper.

Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million

Couple of questions: Why didn't Novartis issue this press release and why is there no Novartis press contact on the release???

SHENZHEN, China, Nov. 9 /PRNewswire-FirstCall/ - Hard To Treat Diseases (HTDS.PK) www.htdsmedical.com, announced today that Novartis, a US$41 billion international healthcare company, is acquiring an 85% stake in HTDS' H1N1 Vaccine partner, Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd., for US$125 million. Novartis of Switzerland will begin a five-year, $1 billion China initiative with two aims: the company will dramatically increase its investment in its China R&D facility, and it will seek to make China one its top three markets worldwide....LINK

Take a look at China Organic Agriculture, Inc. (CNOA), my man

My Man reccomends China Organic Agriculture for long-term gains. Currently trading at $1.06

Check out what Sumfolio says about CNOA. Very positive and I agree:

"In the end, China Organic represents a compelling value given its growth rates and low 2.22x trailing price-earnings multiple. While growth rates may begin to slow this year, investors should still keep a close eye on this under-the-radar Chinese company".

Has Genta's Energizer Bunny of Cancer Drugs Finally Run Out of Juice?

The most surprising thing about last week’s Phase III failure of beleaguered cancer drug Genasense was that Genta’s stock (GETA.OB) fell 70 percent. Seriously, who didn’t see this one coming? Read More

Something to look at, my man

Another look at Ecotality (ETLY), my man

A couple of updates on this promising stock:

November 4, 2009 - ECOtality, Inc. (OTCBB:ETLY), a leader in clean electric transportation and storage technologies, today announced it has entered into definitive agreements with institutional investors, including existing shareholders, for a capital investment of approximately $15.5 million in equity financing....Read more

October 30, 2009 - Nissan is a partner with Scottsdale-based Ecotality and its Phoenix subsidiary, Electric Transportation Engineering Corp., in a $99.8 million federal grant to install charging infrastructure in five states, including Arizona....Read more

Here's a link to my September post about Ecotality.

The China BioPharma/Zhejiang Tianyuan connection, my man

Courtesy of mviramgama on the Yahoo Finance board:

"On May 29, 2006, the Company announced that China BioPharma Limited, a wholly owned subsidiary of the Company, has received approval from Zhejiang Provincial government of the Peoples Republic of China for its investment into Zhejiang Tianyuan Bio-Tech Co., Ltd. China BioPharma Limited will invest US$3,900,000 into Zhejiang Tianyuan Bio-Tech Co., Ltd. for 65% of the ownership. The investment is to be made within 180 days from May 24, 2006, when the operating license of Zhejiang Tianyuan Bio-Tech Co., Ltd. was issued by the government. Peter Wang, the Chairman of the Board of Directors of Techedge Inc., will be the Chairman of the Board of Directors of Zhejiang Tianyuan Bio-Tech Co., Ltd." LINK

Weighing True Cost Of Delays In The Drug-Approval Process

by Thomas Sowell:

"....the question of how safe and how effective, and at what cost, must be considered as regards the years of tests and trials prescribed by the FDA's drug-approval process. The more years that the trials go on and the larger the number of people in the sample taking the drug, the more reliable the end results as to both safety and effectiveness — and the more sick people will be left to suffer and perhaps die while these processes go on." LINK

Open Thread, My Man

Whatever you want to talk about, my man.

One Dozen Small Stocks Survive My Screen Tests

From Bloomberg.com: -- I have nothing against large companies, but my heart belongs to small-cap value stocks.

As I see it, the chances of finding a gem in the rough are greater with small stocks. They are less followed by analysts and investors, so the opportunities haven’t been exhaustively picked over.

Last week I screened the 2,131 U.S. stocks with a market value between $250 million and $2 billion, using these filters:

-- Five-year sales and earnings growth averaging 10 percent a year or better.

-- Debt less than 50 percent of stockholders’ equity.

-- Price-to-earnings ratio below 15, measured on both the actual earnings for the trailing four quarters and the estimated earnings for 2009.

-- Price-to-book ratio (stock price divided by corporate net worth per share) and price-to-sales ratio (stock price divided by per-share sales) both below two.

Here’s a run-down, in alphabetical order, of the stocks that survived these screens....LINK

Take a look at American Oriental Bioengineering, Inc. (NYSE:AOB), my man

American Oriental Bioengineering, Inc. (Public, NYSE: AOB). Currently trading at $4.01 and it has been as high as $13 in recent years and it is a NYSE-traded so we're talking the big-leagues here.

BioCapital China Summit 2009 in Beijing, November 7, 2009, my man

For those interested in the Chinese biotech industry:

This special one-day Summit to be held in conjunction with Beijing’s premier life science conference, the Beijing International Healthcare Industry Forum 2009 (HIF), will explore the state of China’s rapidly growing biotech industry and the financial drivers that will determine its success, including:

• The State of China Biotech
• The Evolving Investment Climate - Issues and Opportunities
• How Government Funds Are Helping Biotech Companies Grow
• How to Attract Funding - What VCs Really Want
• Public Market Financing - Exit Opportunities for Biotech Companies

Plus the SEED Business Plan Competition, organized by Orbimed, McKinsey and Roche and presented by ChinaBio, will be launched as part of the BioCapital China Summit.

LINK

You can see who is sponsoring this event by clicking here.

Novartis wants China as its No. 3 market

From FiercePharma

"Novartis has upped the ante in China. Today, the Swiss drugmaker said it was buying an 85 percent chunk of the Chinese vaccines maker Zhejiang Tianyuan for $125 million. And that's just one-tenth of what Novartis is planning to spend on beefing up R&D in the country..."

Read more:

China Biopharma's big jump today, my man

0.0530 +0.0440 (488.89%)

What is up with the AVAX Technologies website, my man?

I like AVAX Technologies, Inc. (AVXT), my man. It seems like a promising biotech stock but what the hell is up with all their non-working links on their homepage???

Go to their site and you'll see what I mean. Right there on their main page there are two links under "Clinical News" about Phase III trials. They don't work.

Click on the Investor Relations tab and click on "Press Releases". Doesn't work. "Information Request" doesn't work either. Neither does "Stock Information" or "Ownership Profile".

At least I was able to reach their voice-mail on their PA phone number at 215-241-9760.

Will Nuvo Research (NRIFF) get FDA approval?

(PINK:NRIFF, 0.286) Your guess is as good as mine:

Seeking Alpha, August 19, 2009 - Nuvo Research Worth Buying

Press release from October 26, 2009 - Nuvo Research responds to increased trading activity

"While it is Nuvo's policy not to comment on market rumours or speculation, at the request of IIROC, Nuvo is confirming that, as previously disclosed, it anticipates receiving a decision from the United States Food and Drug Administration (FDA) on or about November 4, 2009

pertaining to the approvability of the Company's lead drug Pennsaid(R).

Nuvo has not yet received a decision from the FDA on the approvability of Pennsaid. When the Company does receive a decision from the FDA regarding Pennsaid, it will issue a press release in a timely manner."

Stockhouse, November 3, 2009 - Nickel plays and FDA approval : Best of the Boards/Blogs

Chinese movie studio eyes NYSE listing, my man

Interesting:

HONG KONG (AP) - A third leading Chinese movie studio is aiming for a listing—this time on the New York Stock Exchange—as the country's entertainment companies turn to the capital markets to raise funds. Beijing Polybona Film Distribution Co. is aiming to go public in the second half of next year or the first half of 2011, Chief Executive Yu Dong told The Associated Press in a phone interview Tuesday. The company will start drafting its listing application early next year, he said.

Polybona's rivals are making similar moves. Huayi Brothers Media Corp. debuted on China's new small companies market in the southern city Shenzhen on Friday, surging 148 percent on its first day of trading. The state-run China Film Group is planning to list in Shanghai, spokesman Weng Li told the AP recently. Yu said he wants to list Polybona in the U.S., where entertainment stocks are common, to open up the company to American and other foreign investors.

LINK

Farewell to HEB, my man

Well, not quite, my man. My Stop-Loss for Hemispherx BioPharma (AMEX:HEB) was triggered today when it reached $1.19. I sold 1,800 shares today leaving me with 500 share left stuck with the hope of FDA approval of Ampligen. I originally had 3,000 when this whole thing started back in May.

Based on yesterday's news it doesn't appear to me that there will be approval this year. And I think we all have less reason to trust Hemispherx Biopharma. Since May 25th we were under the impression that we were simply waiting to hear the FDA's verdict. But now it seems that the Ampligen application to the FDA wasn't complete.

I think we can expect to see HEB fall under a dollar. Ampligen may yet still get approved someday, my man. Just not this year.

HTDS coming back up, my man

Go HTDS!

Market Report -- In Play (HEB)

From MSN Money, November 2, 2009:

Hemispherx Biopharma updates chronic fatigue syndrome treatment and commercial application programs; plans to widen its ongoing clinical programs in CFS Co announces announces a two-prong CFS clinical mission for November and December 2009. The company plans to widen its ongoing clinical programs in C.F.S. by accelerating collaborations with a consortium of researchers who have just discovered a retroviral link to Chronic Fatigue Syndrome. With the consortium of researchers at the Whittemore Peterson Institute, the company is also now evaluating the defect in immunosurveillance in specific subsets of C.F.S. patients in a clinical study entitled "Therapeutic Activation of NK lymphocytes to Alleviate Chronic Fatigue Syndrome." These immune defects may be due to the previously undetected retrovirus. The company also plans to complete all outstanding queries from the FDA regarding its New Drug Application for Ampligen, an experimental therapeutic, during Nov and Dec, 2009. LINK

Hemispherx Biopharma responding to FDA’s Ampligen questions

Philadelphia Business Journal, Monday, November 2, 2009:

Hemispherx Biopharma said Monday its plans to “complete all outstanding queries” from the Food and Drug Administration regarding the company’s new drug application for Ampligen this month and next.

The Philadelphia biotechnology company is seeking approval to market Ampligen as a treatment for chronic fatigue syndrome.

Hemispherx (NYSE Amex:HEB) officials said they already issued six reports to the FDA between March 9 and Sept. 15 including clinical safety assessments, specialized pre-clinical toxicology reports, and abbreviated chemistry and manufacturing control reports.

Over the next two months, the company plans to submit an additional four reports that will include pharmacokinetic analyses of the drug in multiple lower animal species and final validation reports of certain manufacturing procedures conducted at an independent facility.

Additionally, Hemispherx said Monday it intends to widen its ongoing clinical programs in chronic fatigue syndrome by accelerating collaborations with a consortium of researchers at the Whittemore Peterson Institute in Reno, Nev., who recently discovered a retroviral link to the disorder. LINK

Readers Ask: A Virus Linked to Chronic Fatigue Syndrome

This should be of interest to HEB investors....

From the New York Times, October 15, 2009:

Readers Ask: A Virus Linked to Chronic Fatigue Syndrome By The New York Times Denise Grady, a science writer for The New York Times, recently explored the link between a recently discovered virus called XMRV and chronic fatigue syndrome, in “Is a Virus the Cause of Fatigue Syndrome?” On the Consults blog, scientists and doctors from the International Association for Chronic Fatigue Syndrome, a society of 500 biomedical and behavioral professionals, took readers’ questions on chronic fatigue syndrome. LINK

Hemispherx BioPharma came really close to my Stop-Loss Order, my man

I have 2,300 shares of Hemispherx Biopharma and my Stop-Loss Order for HEB is $1.25. The stock fell down to $1.31 before closing up at $1.45 last Friday.

After missing out on DNDN and VNDA I jumped into HEB in early May with the hope of catching lighting. My plan was to cash out after FDA approval of Ampligen on May 25th and invest heavily into stocks like CTIC, PFE, LVS, F and HGSI. As you can see, that plan didn't work out as we are still waiting for FDA approval.

To honest I was feeling relieved on Friday at the prospect of getting out of Hemispherx Biopharma. This stock has been nothing but frustration since May. It's not a stock that inspires a whole lot of confidence. I don't know if their CEO has been totally honest with us and the FDA's silence since May gives us nothing but doubts. This is not a biotech with other drugs in the pipeline. Their cheap-looking web site doesn't inspire much assurance.

The stock has attracted a large number of bashers and doubters. President Obama has declared Swine Flu (H1N1) a national emergency. We're in the Fall. People are getting sick and the FDA is still silent on Ampligen. What? They haven't gotten their "staffing" issues resolved yet? But the real problem just may be that U.S. regulations are just too cautious when it comes to approving new drugs.

The money I have tied up in HEB would buy lots of shares in more promising companies like AVXT, MCET, NEOL and VRAL.

On the other hand Ampligen could still get approved. I could have anywhere from $10,000 to $20,000 to play with afterwards. Or the wait could drag out into 2010. Or maybe it won't get approved.

Frustration.

A FORWARD SPLIT for HTDS: What do you think my man?

Results of last month's poll. 190 votes total:

Love it: 45 votes - 23%
A good thing: 39 votes - 20%
Really not sure: 62 votes - 32%
Probably not good: 23 votes - 12%

Hate it: 21 votes - 11%

(I know the percentages add up to 98%. Don't know why but that's what Google generated). As for myself, I voted really not sure but I'm optimistic. I wonder how accurate the poll is. Did people vote more than once? I have 31 followers but very few comments. I hope people will speak out more in the future.

Happy Halloween, my man

Might be worth it to load up on Lifeline Biotech (LLBO), my man

A risk but you never know. LLBO is only 0.0026, From FavStocks.com :

"...More details after contacting Jim Holmes, CEO of Lifeline Biotech, to provide even further clarification of todays news. Jim Holmes has been in contact with their FDA consulting firm who advised the FDA is 30-60 days past the normal time expected to provide a response. The FDA will determine if their technology and testing of over 600 patients would meet the requirements for a 510(k). Jim went further to say that he expects a response on this by the “end of November” but its not guaranteed and its all in the FDA’s hands now. Jim has done everything he possibly can at this point including calling the FDA to get status but the “FDA will not say one word”. LINK

AVAX Currently Pending Clinical Trials News for its Pipeline (OTC:AVXT.PK)

Long item from StocksHaven on October 14th but worth reading if you're in AVXT or thinking about it. Here's the last paragraph:

Overall Sentiment

Having finally managed to find the means for capital in order to fund ongoing research and development costs, all the while establishing stability by joining the OTC market, the company seems to have moved past its most troubled times and onto greener pastures. The end of 2009, and beginning of 2010 should provide a rebirth for AVAX, boosting investor confidence as they begin to focus on the phase II and phase III clinical trials respectively. The results of these trials remains unknown, however, when taking a look at other struggling cancer biotechs which are entering or have entered phase III, it is easy to depict which way this stock and its market cap of 27.10M will go — just take a look at Cell Therapeutics (NASDAQ:CTIC).

LINK

Much needed distraction from biotech stocks in the red, my man

What does Genta offer us now, my man?

The Genta pipeline on their site

Bad news today from Genta, my man

Interim analysis of Phase III data on Genta’s melanoma treatment, Genasense®, revealed that it did not meet one of its primary endpoints or any of the secondary endpoints that are evaluable at this time. The company has thus decided to postpone submission of an NDA this year.

Genta, already trading below $1, lost just over 81% of its value in early morning trading. After closing yesterday at $0.65, it opened today at $0.12....LINK

Genta conference call Thursday October 29, 2009 at 8:00 AM ET, my man

Genta Incorporated (OTCBB: GETA - News) announced that the Company will host a conference call and live audio webcast to review top-line results of its Phase 3 trial of Genasense^® in patients with advanced melanoma. The call will take place on Thursday October 29, 2009 at 8:00 AM ET.

Participants can access the live call by dialing (877) 634-8606 (U.S. and Canada) or (973) 200-3973 (International). The access code for the live call is Genta Incorporated. The call will also be webcast live at http://www.genta.com/investorrelation/events.html.

Good luck to all GETA shareholders! GETA is currently at 0.65 Link to today's press release

Take a look at Mammoth Energy Group (MMTE), my man

A Toucan stock pick...Currently at 0.0005 Here's a link to their site

Why You Can't Get the Swine Flu Vaccine

From today's Wall Street Journal:

Why You Can't Get the Swine Flu Vaccine

U.S. regulations are too cautious. Europe has adopted a more sensible approach.

By SCOTT GOTTLIEB

Though the swine flu is widespread in 46 states many Americans are still waiting to get their vaccines. The Obama administration blames the shortage on manufacturing delays at the five firms making these products. But production issues only explain part of the shortfall. Also to blame are a series of policy decisions that reflect our extreme caution when it comes to these products.

Though the swine flu is widespread in 46 states many Americans are still waiting to get their vaccines. The Obama administration blames the shortage on manufacturing delays at the five firms making these products. But production issues only explain part of the shortfall. Also to blame are a series of policy decisions that reflect our extreme caution when it comes to these products.

From a regulatory standpoint, vaccines are unique in many ways. Since we distribute them widely to otherwise healthy people, they deserve careful oversight. But right now we are shunning new, superior vaccine science by being overly cautious.

The first fateful policy decision, made last spring, was to forgo vaccine additives—called adjuvants—that activate the immune system and make shots more potent. Adjuvants allow a smaller supply of vaccine stock to be stretched across more doses. These adjuvants are included in H1N1 vaccines world-wide, but not in the U.S.

Why do adjuvants matter? An adjuvanted H1N1 vaccine being used in Europe contains 3.75 micrograms of vaccine stock. The same vaccine in the U.S., without the adjuvant, requires 15 micrograms of vaccine for equal potency. If we used adjuvants, we could have had four times the number of shots with the same raw material....

How can we improve our regulatory process to prevent such shortages? First, the Food and Drug Administration (FDA) needs to create a review pathway for adjuvants that can become components of multiple vaccines. One, called monophosphoryl lipid A, was recently the first modern adjuvant to be approved in the U.S.—in this case as part of a vaccine for cervical cancer. We've been slow to integrate vaccine additives, bowing to imprudent activism and litigation. The European strategy of having adjuvants preapproved, as part of mock up pandemic vaccines, was smart. We should adopt it.

Second, the FDA requires vaccines to sit for weeks after they come off the manufacturing line to make sure they haven't grown bacterial impurities. This is why most of the H1N1 vaccine supply is released in waves and won't be ready until later this winter. The FDA can work with manufacturers to develop better standardized tools, called assays, to quickly assess new vaccine....

Click here to read the whole piece

Two great buys under one dollar, my man

Cell Therapeutics closed today at $0.92 and Hard To Treat Diseases is currently at 0.0091

HTDS to acquire a stem cell company, my man?

Interesting, check out this Pink Sheet Filing from yesterday: LINK

And this from their October 12, 2009 press release:

"....This is experimental data that Slavica Biochem group obtained on laboratory animals. Preliminary experiments will begin within a project aimed at promoting stem cell graft survival in the model of traumatic brain injury in rats. The company invites its followers to review all the Pink Sheets filings..."

Keep an eye on BizAuctions (BZCN), my man

This may move up soon. Currently at 0.0013

Check out what SmallCap Networks has to say:

"Finally, BizAuctions Inc. - despite an erratic past - may be working on a breakout move that actually develops some follow-through.

This is nothing more than a notification that things are different now for BizAuctions shares... we have buying volume. We saw a ton of it Friday, and today's isn't bad either. We also saw a couple of heavy accumulation days two weeks ago. It's not a game-changer for BZCN (yet), but clearly something is going on that's different.

As for how I'd handle it, I'd do nothing yet. I'm going to out BizAuctions Inc. on my watchlist, so subscribers to the newsletter may be seeing this name again... either in the community pages or in the e-mail newsletter - I'm not sure. I just get the feeling BZCN could be worth monitoring for a while."

And StockHaven:

"As the holiday season fast approaches during one of the most hard hit economic times in recent memory, certain discount companies look to profit and gain recognition, differentiating themselves from the pack. One of these such companies is BizAuctions Inc. (OTC:BZCN.OB), which is quickly gaining momentum in a $60B excess inventory liquidation market. The concept is simple, they offer eBay liquidation services for companies who have excess inventory, returns, and overstock items. Given that eBay is one of those companies which is recession proof, investors should feel a little more confident should they choose to place their eggs in this basket. At first glance, this may seem like a simple concept, however it made them a hefty revenue of $1,340,904 during six months ended June/30/2009, and that’s not too bad for a high growth company worth an estimated $640M in market cap. Despite the struggling economy, BizAuctions has continued to decrease operating and net losses, all the while maintaining a revived sense of optimism after eBay (NASDAQ:EBAY) hit their highest level in 10-months and exceeded Wall Street’s forecast. BizAuctions alsoruns a retail clothing store named “Lucky 7’s” which opened at the Chula Vista Center, on May/29/09 next to Macy’s in Chula Vista, CA. It is also important to remember that during the last holiday season in December of 2008, the company’s shares reached a one year high of 0.11 price per share."

For a brief shinning moment HTDS was at 0.11 cents today, my man

FDA OKs Use of BioCryst Flu Drug, my man

BIRMINGHAM, Ala. (The Street) The Food and Drug Administration has authorized the emergency use of peramivir, an experimental antiviral drug, to treat swine flu, also known as H1N1 influenza. The drug is being developed by BioCryst (BCRX Quote) LINK

If only they would do this for Ampligen and Hemispherx Biopharma.

Don't forget about ChinaBioToday, my man

Good source of information about the Chinese biotech industry, Click Here

How much longer must we wait for a decision on Ampligen, my man?

"One to two weeks..."

Lots of talk about Biovest International (BVTI.PK), my man

Some people on the Yahoo and Google message boards are saying BVTI is going to be $30, $50, $100 PPS soon....I don't know about that, I'm not invested in this stock. Biovest has had money issues. November 2nd may be a key date. I'm trying to find info about this. In the meantime, see for yourself:

Yahoo Google

BVTI is currently at 0.44. Here's a link to their site.

A little more about Wellstar International (WLSI), my man

I mentioned the other day that I "loaded up" on Wellstar International (WLSI) and I want to stress that I did this because the stock is cheap, not because I believe anything is going to happen, good or bad, with WLSI in the near future. Investing in stocks is kind of like gambling but you have the time to do your research. Spending $35 to get 300,000 shares is not a huge risk. It's money I'm willing to spend on the chance that WLSI will someday be 0.0075 or even just 0.0025. It's just a chance to make extra money someday.

Can we have a Friday touchdown, my man?

Come on HEB, IMGG, BIEL, HTDS, NEPH....somebody take off like a rocket today

NeoPharm, Inc. (OTC: NEOL), my man

NeoPharm continues to climb up as I mentioned before here.

Articles:

NeoPharm Tipped As Stock to Watch

An Exciting Upcoming 4Q09 For NeoPharm

NeoPharm (OTC: NEOL.PK): A Pipeline with Multiple Catalysts

I have loaded up on Wellstar International (WLSI), my man

Which is not to say I have great faith that WLSI will ever be $1 or even a penny. But its so cheap at 0.0002 and it's always among the highest active volume stocks traded on the OTC BB. It doesn't have to go up very much to generate some easy profit.

Hard To Treat Diseases at 0.0100, my man

Obviously HTDS stock owners aren’t too happy about the current price at 0.0100. I’m not. A while back I predicated that HTDS would be somewhere between 0.05 and 0.10 by October and I thought maybe I was being conservative. But I think most HTDS shareholders including myself are still confident that HTDS is going to pay off big-time at some point. HTDS continues to issue positive press releases but solid information such as the Q3 financials may give HTDS the boost it needs. I don’t doubt for a moment that we’ll see HTDS back at 0.02 and beyond in the not so distant future.

You think HEB sucks? I understand, my man

What a frustrating stock to own and we may not hear from the FDA about Ampligen until sometime in 2010. It's not all Hemispherx BioPharma's fault. The FDA should have issued another definitive date for approval or an official update of sort kind after saying back in May that they needed another "one to two weeks". After five months of waiting we still don't know what hell is going on.

No big CTIC bump today, my man

Odd considering the positive news from yesterday. I thought it would close today over $1.20 today at least but CTIC is worth hanging on to, my man.

Keep an eye on Cell Therapeutics on Thursday, my man

Some very good news from CTIC released a little while ago:

Pixantrone Produces High Rates of Complete Remission in Multiple Relapsed and Refractory Indolent and Aggressive Non-Hodgkin's Lymphoma

Pixantrone Produces High Rates of Complete Remission in Multiple Relapsed and Refractory Indolent and Aggressive Non-Hodgkin's Lymphoma Overview of Phase II-III Clinical Trials will be Presented at International Lymphoma Meeting

SEATTLE, Oct. 22 / Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced that Dr. Richard Van der Jagt of the Ottawa General Hospital will present at the Lymphoma and Myeloma 2009 Conference in New York an overview of CTI's pixantrone phase II and phase III clinical studies that demonstrated high rates of complete remission (CR) in relapsed/refractory aggressive and indolent non-Hodgkin's lymphoma (NHL) patients.....LINK

Ampligen is still in limbo, my man

October 16, 2009, Washington Business Journal:

A decision on Hemispherx BioPharma’s new drug application for Ampligen, twice delayed by the FDA earlier this year, is still in limbo.

William A. Carter, CEO of the Center City biotech company, said last week the company is responding to issues raised by the Food and Drug Administration during its review of Ampligen, an experimental treatment for chronic fatigue syndrome.

Hemispherx has spent more than $500 million and more than three decades developing the drug.

Carter last week provided an update on the status of the FDA’s review of Ampligen to BioMedReports, a Web site that provides information on life sciences firms.

“We continue to be in contact with the [FDA] concerning certain requests they have made over the last year that have to do with toxicology,” Carter said. “This is nonclinical work on the drug. We have continued to complete reports and we expect to sometime this quarter, the fourth quarter, complete a set of requirements [from the FDA] that have to do with preclinical toxicology.”

In its latest quarterly report filed with the Securities and Exchange Commission, Hemispherx noted it is working with the Lovelace Respiratory Research Institute in Albuquerque, N.M., on animal toxic studies in support of its Ampligen application.

The August filing noted the studies were requested by the FDA and that the studies were “substantially completed,” with summary reports issued to the agency during the third quarter.

“Data for final FDA reports are presently undergoing internal auditing at Lovelace and Hemispherx with a projected completion of the final report for late 2009 to early 2010,” the company stated in the filing....

Click here for the whole article.

Speculative stock: China SXAN Biotech, Inc. (Public, OTC:CSXB), my man

I just came across this company a little while ago. Don't know anything about it and I'll take a look at tomorrow:

China SXAN Biotech, Inc. (Public, OTC:CSXB): China SXAN Biotech, Inc., formerly Advance Technologies, Inc., is a development-stage company. On July 10, 2007, the Company acquired the outstanding capital stock of American SXAN Biotech, Inc. (American SXAN). American SXAN is a holding company that on October 31, 2006, acquired 100% of the stock of Tieli Xiaoxinganling Forest Breeding Co., Ltd. (Tieli Xiaoxinganling). Tieli Xiaoxinganling is engaged in the business of manufacturing and marketing wines and tonics derived from domesticated forest frogs.

Keep an eye on AVAX Technologies (AVXT), my man

This is another long-term stock I like. I meant to include this in my October 13th post about long-term stocks. Currently at 0.21

Damn!

Aby Rulloda is not only a model and a gogo dancer, but trains and fights Muay Thai. DAMN!

Have a nice weekend, my man

Dreams can come true, it could happen to you

FDA - Federal Delay Agency

ANPI, HEB, NEPH and now BIEL?

FierceBiotech: On the Radar: Keep an eye on these biotech stocks

Fierce Biotech says to keep an eye on these biotech stocks:

Human Genome Sciences (HGSI) $19.16

Auxilium Pharmaceuticals (AUXL) $34.70

Inspire Pharmaceuticals (ISPH) $5.57

GTx (GTXI) $10.75

Poniard Pharmaceuticals (PARD) $.6.92

Hemispherx BioPharma today, my man

$1.81 and waiting...

Some of my favorite long-term stocks,my man

Long-term can have a vague meaning to some as different people will likely have different ideas as to what "long-term" is. For me, when I say long-term, it generally means I'm willing to hold a stock and wait anywhere from 3 months to a year or more. I'm not expecting any big gains in the near future with these stocks but I'm confident that at least some of them will pay off at some point:

Advanced Cell Technology, Inc. (ACTC)
Angiotech Pharmaceuticals, Inc. (ANPI)
Capital Trust (CT)...when the economy recovers this should return to $30
China Precision Steel, Inc. (CPSL)...China is a growing country and you build things with steel
Cell Therapeutics, Inc (CTIC)
Ecotality, Inc. (ETLY)...Electric cars are in our future
Genta Incorporated (GETA)
Hana Biosciences, Inc. (HNAB)
Imaging Diagnostic Systems, Inc. (IMDS)
MultiCell Technologies, Inc (MCET)
Neopharm Inc. (NEOL)
Oilsands Quest Inc. (BQI)...lots of potential oil
Peregrine Pharmaceuticals, Inc. (PPHM)
Palatin Technologies, Inc. (PTN)
RegeneRx Biopharmaceuticals, Inc (RGN)
Solos Endoscopy, Inc. (SNDY)
Viral Genetics, Inc (VRAL)

ASFX and IMDS doing well today, my man

American Scientific Resources (ASFX) Imaging Diagnostic Systems (IMDS)

MultiCell Technologies, Inc. is 'One to Watch', my man

This article on the International Business Times site appeared in August but I believe MultiCell Technologies is a good long-term stock to consider. Take a look, MCET is still pretty cheap at 0.02 :

MultiCell Technologies, Inc. (MCET.OB) is 'One to Watch'

Headquartered in Woonsocket, Rhode Island, MultiCell Technologies, Inc. is an integrated biopharmaceutical company. Trading on the OTCBB, their commitment is to the development of breakthrough therapeutics based on a portfolio of therapeutic candidates and patented drug development technologies. The company plans to pursue strategic alliances to better penetrate the various markets for their therapeutics.

The company’s drug development program focuses on the modulation of the immune system. Their lead drug candidates include drugs to treat multiple sclerosis (MS)-related chronic fatigue, relapsing-remitting MS, type-1 diabetes, and infectious disease. MultiCell Technologies, Inc.’s therapeutic pipeline includes MCT-125, which is directed at treating chronic fatigue in MS patients. MCT-125 completed a 138 patient Phase II clinical trial and demonstrated strong efficacy in reducing fatigue in MS patients....Click here to read the rest.

Will this be the week that BioElectronics busts out, my man?

Industry leaders express concern as FDA clamps down on 510(k)s

From the Massachusetts Medical Devices Journal:

An internal Food & Drug Administration memo leaked by the Wall Street Journal indicating that the Food & Drug Administration plans to tighten up its 510(k) approval process for medical devices has industry leaders expressing concern.

According to the memo, written by FDA device evaluation office head Donna-Bea Tillman, the agency is already clamping down on the 510(k) process, by which the majority of medical devices are approved.

"It's Autumn, and change is in the air. This is particularly true for our 510k program," Tillman wrote, according to the Journal, adding that in order to "get a better lay of the land" branch chiefs are now required to pass along applications for devices with a new "indication" or use "that you have never cleared for that device type."

That's a deviation from former FDA protocol, two FDA scientists told the newspaper. But new protocol is "just the first of what I am sure will be many things that we will be doing to strengthen the 510k and all of our other programs in the months ahead," Tillman wrote.

Thomas Sommer, president of MassMEDIC, the Massachusetts medical device industry council, told MassDevice that the 510(k) procedure, which is used for devices that are "substantially equivalent" to products already on the market, is one of the world's most stringent approval processes.

"Our concern as an industry is that this change in protocol will bring us back to the days in the mid-1990s when 510(k)s took well over a year for FDA to clear," Sommer told us. "This industry is one of the most heavily regulated industries. It complies with FDA guidelines and regulations on everything from developing products to manufacturing to marketing and sales. Companies do a very good job of complying with a vast web of regulations.

"Our companies already comply with the toughest product review protocol in the world. It's viewed as the gold standard and most companies are delighted to go though the process, because it means they have achieved the highest certification of safety and effectiveness in the world."

A Johnson & Johnson spokeswoman sounded a similar note in speaking with the Journal, saying that adding evidentiary requirements to the 510(k) process "would raise development costs substantially while also creating barriers to market entry that would reduce competition."

Click here to read the rest of this article

ZZZZZZZZ....Hemispherx BioPharma, my man

The slumber continues...

Interview with Dr. William Carter, CEO of Hemispherx Biopharma

"An interview with Dr. William Carter, CEO of Hemispherx Biopharma (AMEX:HEB) regarding the status of the NDA for Ampligen as a first line treatment for Chronic Fatigue Syndrome as well as his company's pipeline plans for Alferon LDO (Low Dose Oral) application." - That's nice but all I want to know now is if Ampligen is going to be approved or not by the FDA. WTF is going on?

What happens on Friday with Hemispherx BioPharma, my man?

???

Keep an eye on Imaging3, Inc. (IMGG), my man

IMGG has climbed from .04 in August to 0.70 today as it awaits FDA approval.

Nice day for Hard to Treat Diseases (HTDS), my man

Finished at 0.0150 and the company issued the following release today:

Hard to Treat Diseases (HTDS) Obtains GMP Certificate from Russian FDA

Update on NeoPharm (NEOL), my man

On September 10th I mentioned NeoPharm as a good long-term bio-tech stock to get into. After a voluntary delisting from Nasdaq earlier this year NEOL has climbed from 0.07 in February to it's current price at 0.39 on the OTC BB.

Neopharm has 5 drug product candidates in various stages of clinical and pre-clinical development for the treatment of cancer, interstitial pulmonary fibrosis and asthma. The company has cash on hand to fund anticipated development activities into the second quarter of 2010.

Below is a link from an article on NeoPharm from OneMedPlace.

NeoPharm: A Pipeline with Multiple Catalysts

I don't know what the future holds for NEOL but if you invest in enough companies like this your patience should be rewarded. Buy low, sell high and be patient, my man.

Just because I can, my man

HO HTDS, I mean, GO HTDS!

Peregrine Pharmaceuticals, Inc. (PPHM), my man

MYMAN got into Peregrine Pharmaceuticals (PPHM) last year. There's been no big payoff yet but I'm stickin' with PPHM. They reported positive news this week on their drug bavituximab (see below) But the company may do a reverse split within a month to remain trading on Nasdaq.

Currently trading at 0.68

October 5, 2009: Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial

Advanced Cell Technology now on the OTCBB, my man

WORCESTER, Mass.--Advanced Cell Technology, Inc. (Advanced Cell, ACT) (OTCBB: ACTC - News) announced today that effective immediately the Company's shares will be traded on the Over-the-Counter Bulletin Board under its previous ticker symbol ACTC. The Company is now fully reporting and up-to-date with all of its filing requirements. The Company’s stock had previously traded on the Pink Sheets. LINK

Good long-term stock, my man. Currently trading at 0.13

Transdel Pharmaceuticals announces positive Phase 3 study results for Lead Topical Pain Drug Ketotransdel(R), my man

But the stock doesn't really go anywhere. Currently at $2.12.

Cell Therapeutics is a buy under a $1, my man

Question is, how far will CTIC drop? 0.96 right now

Transdel Pharmaceuticals: Phase 3 clinical study results to be announced October 6, my man

Transdel Pharmaceuticals, Inc. (OTC Bulletin Board: TDLP) today announced that it will host a conference call and audio webcast on Tuesday, October 6, 2009 at 9:00 am, eastern, to announce the top-line results of its Phase 3 clinical study for Ketotransdel®, a topical cream based non-steroidal anti-inflammatory drug ("NSAID") for acute pain. A press release will be issued on Tuesday, October 6, 2009 at 7:30 am, eastern.

The CEO of Angiotech Pharmaceuticals (ANPI) brought 49,500 shares of ANPI, my man

President and CEO of Angiotech Pharmaceuticals Inc. (ANPI) William L Hunter buys 49,500 shares of ANPI on 09/29/2009 at an average price of $1.9 a share.

Angiotech Pharmaceuticals Inc. is a Canadian pharmaceutical company dedicated to the development of medical device coatings and treatments for chronic inflammatory diseases through reformulation of the anticancer drug paclitaxel. These treatments are based upon the company's discovery that paclitaxel blocks an important cellular pathway involved in inflammation. The company's goal is to establish a leadership position in the development of treatments for chronic inflammatory diseases. Angiotech Pharmaceuticals Inc. has a market cap of $146.6 million; its shares were traded at around $1.76 with and P/S ratio of 0.5.

LINK

Take a look at AVAX Technologies, (OTC:AVXT), my man

AVAX Technologies, Inc. (AVAX) is a development stage biotechnology company specializing in the development and future commercialization of individualized vaccine therapies and other technologies for the treatment of cancer. The Company's vaccine consists of autologous (the patient’s own) cancer cells that have been treated with a chemical (haptenized) to make them more visible to the patient’s immune system. AVAX refer to its cancer vaccine technology as autologous cell vaccine immunotherapy and to the vaccine as the AC Vaccine. Its clinical trials for the AC Vaccine have concentrated on melanoma, ovarian carcinoma, which are its primary indications, and non-small cell lung cancer. The Company refers to its AC Vaccine candidates as: M-Vax, L-Vax and O-Vax. M-Vax is for the treatment of melanoma. L-Vax is for the treatment of non-small cell lung cancer. O-Vax is for the treatment of ovarian cancer.

Currently trading at 0.0770.

Related article: Melanoma Drug Called a “Breakthrough” After Study

ScienceDaily: Umbilical Cord Blood As A Readily Available Source For Off-the-shelf, Patient-specific Stem Cells

Can you say, Cord Blood America Inc. (CBAI.OB), my man?


Umbilical Cord Blood As A Readily Available Source For Off-the-shelf, Patient-specific Stem Cells

ScienceDaily (Oct. 2, 2009) — Human umbilical cord blood cells may be far more versatile than previous research has indicated. Scientists report that they have successfully reprogrammed human umbilical cord blood cells into cells with properties similar to human embryonic stem cells. The results are significant as they identify cord blood as a convenient source for generating cells with a theoretically limitless potential.

Umbilical cord blood cells can successfully be reprogrammed to function like embryonic stem cells, setting the basis for the creation of a comprehensive bank of tissue-matched, cord blood-derived induced pluripotent stem (iPS) cells for off-the-shelf applications, report researchers at the Salk Institute for Biological Studies and the Center for Regenerative Medicine in Barcelona, Spain. "Cord blood stem cells could serve as a safe, "ready-to-use" source for the generation of iPS cells, since they are easily accessible, immunologically immature and quick to return to an embryonic stem cell-like state," says Juan-Carlos Izpisúa Belmonte, Ph.D., a professor in the Salk's Gene Expression Laboratory, who led the study published in the October issue of the journal Cell Stem Cell.

Link to rest of this article.

FDA calendar for October, my man

10/8 Spectrum Pharmaceuticals (SPPI)
10/15 BioElectronics Corporation (BIEL) Allay Pain Relief Patch?
10/19 Amgen (AMGN)
10/22 Biogen Idec (NASDAQ:BIIB) and Acorda Therapeutics (NASDAQ:ACOR)
10/30 GTx, Inc (GTXI), Transcept Pharmaceuticals (NASDAQ:TSPT)

What's missin'?